Multiscale analysis and optimal glioma therapeutic candidate discovery using the CANDO platform

Area of Science:

• Computational biology
• Drug discovery
• Oncology

Background:

• Glioma is an aggressive brain tumor with limited therapeutic options.
• Novel drug discovery strategies are crucial for improving patient outcomes.

Purpose of the Study:

• To employ the Computational Analysis of Novel Drug Opportunities (CANDO) platform for multiscale therapeutic discovery to predict new glioma therapies.
• To identify novel drug candidates and key molecular targets for glioma treatment.

Main Methods:

• Utilized the CANDO platform to compute interaction scores between drug libraries and proteins, generating "interaction signatures".
• Ranked compounds based on signature similarity to approved drugs and consensus across similarity lists.
• Benchmarked CANDO performance by recovering known drugs and identifying novel predictions supported by literature analysis.

Main Results:

• CANDO demonstrated improved accuracy in identifying glioma-associated drugs compared to random controls.
• Identified 24 potential glioma treatments, including approved drugs (e.g., vitamin D, taxanes) and investigational compounds (e.g., ginsenosides, chrysin).
• Key predicted targets include Vitamin D3 receptor, cyclin-dependent kinase 2, and dihydrofolate reductase.

Conclusions:

• The CANDO platform's multitarget, multiscale framework is effective for identifying glioma drug candidates.
• This approach provides a powerful tool for rational drug repurposing and discovery for brain tumors.
• The findings inform new strategies for improving the treatment of malignant gliomas.